Replicon MDF Portfolio Outperforms Benchmark Index Fourth Year in a Row

Replicon Medical Development Fund (MDF) beats Nasdaq Biotech Index (NBI) return for the fourth year in a row. During the year ending on 29th of January return of the MDF portfolio was +9.8 per cent compared to Nasdaq Biotech Index return of -0.7 per cent.


If we assume historical 13 per cent as the expected future biotech market return, we can calculate that the expected annual return of MDF is some 27 per cent. For further information, see previous articles on MDF (or RBV) published on 29th of Jan, 2004, 29th of Jan, 2005, and on 29th of Jan, 2006. See also Performance report ( in Finnish).


This asset management advisory service fits extremely well into our overall service offering because the portfolio is updated only bi-annually. Thus most of our time we can concentrate on our main business, i.e. advisory services for individual corporate and other clients, says Petteri Hirvonen, CEO of Replicon Group.


For further information, please contact: Petteri Hirvonen, CEO, Replicon Group +358-(0)50-552 96 33 This email address is being protected from spambots. You need JavaScript enabled to view it.

Replicon Group is an independent corporate finance, strategic consulting and asset management advisory house based in Helsinki. Replicon provides strategic and financial solutions that facilitate business activities, efficiency, and increase profitability of corporations and other organizations. Our core competence is in the corporate solutions that facilitate and govern growth of businesses based on innovation. An important part of our activities is continuous learning. We want to find and develop most suitable solutions to our customer needs. Replicon Group’s special focus areas are and ICT/Mobile and Life-Science sectors. The main shareholders in Replicon Group are its key management, holding majority of the company’s shares. Replicon’s homepage is